Sign In
Buy URGN
$26.60
+0.0600 (+0.226%)
At Close: Jun 03, 2026
Piper starts 'underestimated' UroGen Pharma with an Overweight
06:27am, Tuesday, 19'th Aug 2025
As previously reported, Piper Sandler initiated coverage of UroGen Pharma with an Overweight rating and $36 price target. Investors are starting to gain more confidence in the Zusduri launch, but the
UroGen Pharma: Targeting Profits In 2027
03:34pm, Monday, 18'th Aug 2025
UroGen Pharma Ltd. recently secured FDA approval for Zusduri, its second commercial product, which is expected to significantly boost future revenues. Analysts remain bullish, with multiple Buy rating
UroGen Pharma Ltd. (URGN) Q2 2025 Earnings Call Transcript
03:05am, Saturday, 09'th Aug 2025
UroGen Pharma Ltd. (NASDAQ:URGN ) Q2 2025 Earnings Conference Call August 7, 2025 10:00 AM ET Company Participants Christopher Degnan - Chief Financial Officer David Lin - Chief Commercial Officer Eli
Urogen Pharma (URGN) Reports Q2 Loss, Lags Revenue Estimates
10:16am, Thursday, 07'th Aug 2025
Urogen Pharma (URGN) came out with a quarterly loss of $1.05 per share versus the Zacks Consensus Estimate of a loss of $0.82. This compares to a loss of $0.91 per share a year ago.
UroGen Pharma Expands Commercial Portfolio with Launch of ZUSDURI™ and Reports Second Quarter 2025 Financial Results
08:00am, Thursday, 07'th Aug 2025
ZUSDURI™ (mitomycin) for intravesical solution now available as the first and only FDA-approved medication for adults with recurrent low-grade intermediate-risk non-muscle invasive bladder cancer (L
24-month Duration of Response (DOR) of 72.2% by Kaplan-Meier estimate was attained in patients who achieved a complete response (CR) at three months (79.6%) PRINCETON, N.J., Aug. 05, 2025 (GLOBE NEWSW
UroGen Pharma to Report Second Quarter 2025 Financial Results on Thursday, August 7th, 2025
08:00am, Tuesday, 29'th Jul 2025
Conference Call and Webcast Scheduled for Thursday, August 7 th , 2025, at 10:00 AM ET PRINCETON, N.J., July 29, 2025 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd.
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In UroGen Pharma (URGN) To Contact Him Directly To Discuss Their Options
PRINCETON, N.J., July 28, 2025 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd.
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In UroGen Pharma (URGN) To Contact Him Directly To Discuss Their Options
ATLANTA, July 21, 2025 (GLOBE NEWSWIRE) -- A shareholder class action lawsuit has been filed against UroGen Pharma Ltd. (“UroGen” or the “Company”) (NASDAQ: URGN). The lawsuit alleges that Def
3 Bullish Biotech Stocks With Explosive Growth Trends
11:03am, Monday, 21'st Jul 2025
Investing in biotechnology stocks is similar to the drug development process itself. That is, investors frequently experience long periods of nothing much happening, interrupted by periods of sharp mo
PRINCETON, N.J., July 21, 2025 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions for urothelial and specialty ca
UROGEN ALERT: Bragar Eagel & Squire, P.C. Urges Investors in UroGen Pharma (URGN) to Inquire About Their Rights in Class Action Lawsuit
10:58am, Saturday, 19'th Jul 2025
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In UroGen Pharma (URGN) To Contact Him Directly To Discuss Their Options
SAN DIEGO, July 17, 2025 (GLOBE NEWSWIRE) -- Robbins LLP reminds stockholders that a class action was filed on behalf of investors who purchased or otherwise acquired UroGen Pharma Ltd. (NASDAQ: URGN
